Search results for "BREAST-CANCER"

showing 10 items of 27 documents

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab pl…

2019

10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological complete response rate was observed in HER2+ breast cancer. This study aims to investigate the added benefit of using both HER2 targeting drugs (T alone or the combination of T + P), in combination with perioperative CT for localized HER2+ GC. This is a prospective, randomized, open-label, phase II trial. HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined.…

Male0301 basic medicineCancer ResearchEsophageal NeoplasmsReceptor ErbB-2SURGERYmedicine.medical_treatmentGastroenterologyStudy ProtocolNEOADJUVANT CHEMOTHERAPYAntineoplastic Agents Immunological0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesOXALIPLATINNetherlandsAged 80 and overDOCETAXELMiddle AgedOPEN-LABELlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChemotherapy regimenNeoadjuvant TherapyProgression-Free SurvivalTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleGastro-esophageal junction cancerEsophagogastric JunctionFluorouracilPertuzumabmedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsCAPECITABINEAdenocarcinomaAntibodies Monoclonal Humanizedlcsh:RC254-282CapecitabineYoung Adult03 medical and health sciencesBreast cancerStomach NeoplasmsInternal medicineHER2Republic of KoreaREGRESSIONGeneticsmedicineHumansBREAST-CANCERPerioperative PeriodAgedCisplatinChemotherapyPerioperative chemotherapyPertuzumabbusiness.industryTrastuzumabmedicine.diseaseOxaliplatin030104 developmental biologyCisplatinbusinessGastric cancerFollow-Up Studies
researchProduct

Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG …

2017

Background Little information is available about the geo-economic variations in demographics, management, and outcomes of patients with acute respiratory distress syndrome (ARDS). We aimed to characterise the effect of these geo-economic variations in patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE). Methods LUNG SAFE was done during 4 consecutive weeks in winter, 2014, in a convenience sample of 459 intensive-care units in 50 countries across six continents. Inclusion criteria were admission to a participating intensive-care unit (including transfers) within the enrolment window and receipt of invasive or non…

MaleARDSdemographyeconomicmedicine.medical_treatmentTerapéuticaair conditioningComorbidityintensive care unitdeveloped country0302 clinical medicineneuromuscular blockingmiddle agedacute myocardial-infarctionmiddle income countryProspective StudiesGeography Medicalcritically-ill patientsadultagedpriority journalrisk factorIncomegeographic-variationDeveloped countryhospitalizationprospective studyHumanPulmonary and Respiratory MedicineDeveloped Countriemedicine.medical_specialtyDeveloping countryArticle/dk/atira/pure/subjectarea/asjc/2700/274003 medical and health sciencesSíndrome respiratorio agudo graveunitsMedicalHumansIntensive care medicineDeveloping CountriesAgedhigh income countryRespiratory Distress Syndrome Adultnoninvasive ventilationAparato respiratoriomedicine.diseasemortalitymajor clinical studyProspective Studiearterial oxygen tension030228 respiratory systemARDSObservational studySociologíahealth care deliverygeographyintensive-careRisk FactorsEpidemiologyProspective cohort studyRespiratory Distress Syndromepartial pressureartificial ventilationSociología médicaMiddle Agedadult respiratory distress syndromeAged; Comorbidity; Delivery of Health Care; Developed Countries; Developing Countries; Europe; Female; Geography Medical; Humans; Income; Intensive Care Units; Male; Middle Aged; Patient Outcome Assessment; Prospective Studies; Respiratory Distress Syndrome Adult; Risk Factors; Pulmonary and Respiratory MedicineEuropeIntensive Care UnitsfemaleincomeFemaleEnfermedadinjurycohort analysigross national incomesurvivalNOmedical geographyDeveloping Countrielength of staymedicinecontrolled studyoutcome assessmentbreast-cancerMechanical ventilationdiseasebusiness.industryDeveloped Countriespatient caredeveloping country030208 emergency & critical care medicinestatistics and numerical data AgedComorbiditywinterACUTE MYOCARDIAL-INFARCTION; CRITICALLY-ILL PATIENTS; GEOGRAPHIC-VARIATION; INTENSIVE-CARE; BREAST-CANCER; MORTALITY; DISEASE; INJURY; UNITS; HOSPITALIZATIONPatient Outcome AssessmentEmergency medicineprone positiontreatment outcomebusinessDelivery of Health Care
researchProduct

Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens

2019

Anthracyclines are the cornerstone for many oncologic treatments, but their cardiotoxicity has been recognized for several decades. Female subjects, especially before puberty and adolescence, or after menopause, seem to be more at increased risk, with the prognostic impact of this sex issue being less consistent compared to other cardiovascular risk factors. Several studies imply that sex differences could depend on the lack of the protective effect of sex hormones against the anthracycline-initiated damage in cardiac cells, or on differential mitochondria-related oxidative gene expression. This is also reflected by the results obtained with different diagnostic methods, such as cardiovascu…

MaleCardiac & Cardiovascular SystemsMagnetic Resonance Spectroscopyand protection from anthracycline cardiotoxicitymedicine.disease_causeBioinformaticsRisk FactorsAnthracycline cardiotoxicityGender differenceGender differencesAnthracyclinesGonadal Steroid Hormones1102 Cardiorespiratory Medicine and HaematologyAMERICAN SOCIETYCardioprotectionSex CharacteristicsHeartPrognosisMitochondriaMenopauseEchocardiographyReperfusion InjuryHEART-FAILUREAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicity; Anthracyclines; Biomarkers; Cardiotonic Agents; Cardiotoxicity; Echocardiography; Female; Gonadal Steroid Hormones; Heart; Heart Failure; Humans; Magnetic Resonance Spectroscopy; Male; Mitochondria; Nuclear Medicine; Oxidative Stress; Prognosis; Reperfusion Injury; Risk Factors; Sex CharacteristicsFemaleCardiology and Cardiovascular MedicineLife Sciences & BiomedicinePOSITION PAPERCARDIAC DYSFUNCTIONCardiotonic AgentsAnthracyclineSPECKLE-TRACKINGIschemiaDRUG CARDIOTOXICITYPathophysiologymedicineHumansCHILDHOOD-CANCER SURVIVORSBREAST-CANCERPathophysiology monitoring and protection from anthracycline cardiotoxicityHeart FailureCardiotoxicityScience & Technologybusiness.industryWORKING GROUPmedicine.diseaseCardiotoxicityOxidative StressmonitoringCardiovascular System & HematologyHeart failureCardiovascular System & CardiologyRISK-FACTORSNuclear MedicinebusinessOxidative stressAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicityBiomarkersHormone
researchProduct

Cancer costs and outcomes for common cancer sites in the Finnish population between 2009–2014

2018

The cost of cancer and outcomes of cancer care have been discussed a lot since cancer represents 3-6% of total healthcare costs and cost estimations have indicated growing costs. There are studies considering the cost of all cancers, but studies focusing on the cost of disease and outcomes in most common cancer sites are limited. The objective of this study was to analyze the development of the costs and outcomes in Finland between 2009 and 2014 per cancer site.The National cost, episode and outcomes data were obtained from the National register databases based on International Statistical Classification of Diseases (ICD)-10 diagnosis codes. Cost data included both the direct and indirect c…

MaleENGLANDTreatment outcomesairaalahoitocosts0302 clinical medicineFinnish populationavohoitoNeoplasmsHealth careRegistries030212 general & internal medicineta512Finlandhealth care economics and organizationsta316Aged 80 and overnon-institutional careNeoplasms therapyta3142Health Care CostsHematologyGeneral MedicineMiddle Agedkustannukset3. Good healthSurvival RateTreatment OutcomeOncology030220 oncology & carcinogenesisNORWAYSURVIVALHealth ResourcessyöpätauditFemaleSick LeaveCOUNTRIESAdultsairaalatmedicine.medical_specialtyMEDLINEUNITED-STATEShoito03 medical and health sciencesBreast cancerSuomiECONOMIC BURDENmedicineBREAST-CANCERHumansRadiology Nuclear Medicine and imagingIntensive care medicineSurvival rateAgedbusiness.industryCancercancerous diseasesCAREta3122medicine.diseasehospitalsbusinesshospital careActa Oncologica
researchProduct

Hormone replacement therapy enhances IGF-1 signaling in skeletal muscle by diminishing miR-182 and miR-223 expressions : a study on postmenopausal mo…

2014

MiRNAs are fine-tuning modifiers of skeletal muscle regulation, but knowledge of their hormonal control is lacking. We used a co-twin case-control study design, that is, monozygotic postmenopausal twin pairs discordant for estrogen-based hormone replacement therapy (HRT) to explore estrogen-dependent skeletal muscle regulation via miRNAs. MiRNA profiles were determined from vastus lateralis muscle of nine healthy 54-62-years-old monozygotic female twin pairs discordant for HRT (median 7 years). MCF-7 cells, human myoblast cultures and mouse muscle experiments were used to confirm estrogen's causal role on the expression of specific miRNAs, their target mRNAs and proteins and finally the act…

MaleMICRORNASMonozygotic twinmenopausePATHWAYMice0302 clinical medicineMyocyteInsulin-Like Growth Factor IIN-VIVO0303 health sciencesphosphorylationAge FactorsBREAST-CANCER CELLSWOMENMiddle Aged3142 Public health care science environmental and occupational healthPostmenopauseESTROGENmedicine.anatomical_structureMCF-7 CellsmTORGROWTHFemaleAUTOPHAGYMESSENGER-RNASignal TransductionIGF-1 receptormedicine.medical_specialtyHormone Replacement Therapymedicine.drug_classmiR-142-3pBiology03 medical and health sciencesInternal medicinemicroRNAmedicineAnimalsHumansMuscle SkeletalProtein kinase BPI3K/AKT/mTOR pathwayAged030304 developmental biologyAKTagingSkeletal muscleOriginal ArticlesTwins MonozygoticCell BiologyAKT; FOXO3A; IGF-1 signaling; IGF-1R; aging; mTOR; menopause; miR-142-3p; miR-182; miR-223; phosphorylationmiR-223EndocrinologyEstrogenCase-Control StudiesmiR-1823121 General medicine internal medicine and other clinical medicineFOXO3AIGF-1 signalingIGF-1R030217 neurology & neurosurgeryHUMAN LONGEVITYHormone
researchProduct

Total, red and processed meat consumption and human health: an umbrella review of observational studies

2022

Meat consumption has represented an important evolutionary step for humans. However, modern patterns of consumption, including excess intake, type of meat and cooking method have been the focus of attention as a potential cause of rise in non-communicable diseases. The aim of this study was to investigate the association between total, red and processed meat with health outcomes and to assess the level of evidence by performing a systematic search of meta-analyses of prospective cohort studies. Convincing evidence of the association between increased risk of (i) colorectal adenoma, lung cancer, CHD and stroke, (ii) colorectal adenoma, ovarian, prostate, renal and stomach cancers, CHD and st…

MaleMeatRANDOMIZED CONTROLLED-TRIALSprocessed foodsBLADDER-CANCERcolorectal cancerANIMAL SOURCE FOODSmeta-analysiESOPHAGEAL CANCER-RISKCOLORECTAL-CANCERprocessed foodcardiovascular diseaseRisk FactorsTotal meatBREAST-CANCERcancerHumansCookingProspective StudiesSettore MED/49 - Scienze Tecniche Dietetiche Applicatecoronary heart diseasenon-communicable diseaseprocessed meatumbrella reviewevidencefood and beveragesnon-communicable diseasesDietmeta-analysisStrokeObservational Studies as TopicRed MeatDOSE-RESPONSE METAANALYSISFATTY-ACIDSNON-HODGKIN-LYMPHOMAColorectal NeoplasmsDIETARY FACTORSFood ScienceInternational Journal of Food Sciences and Nutrition
researchProduct

Management of elderly patients suffering from cancer: Assessment of perceived burden and of quality of life of primary caregivers

2017

International audience; Objective: To evaluate the perceived burden and the quality of life (QoL) at 3 and 6 months of the primary caregiver (PC) of patients aged 70 and over suffering from cancer and the predictors of QoL in this population.Methods: In this prospective observational study, 98 patients aged 70 and older with cancer and 96 PCs were included between 01/06/2014 and 18/03/2015. The Medical Outcomes Study 12-item Short Form Health Survey (SF-12) was used to assess the QoL of PCs and the Zarit Burden Interview (ZBI) was used to measure the perceived burden at 3 and 6 months. The major determinants of QoL were identified using mixed linear models for the dimensions of the SF-12 th…

MaleMultivariate analysisActivities of daily livingTime Factors0302 clinical medicineQuality of lifeCost of IllnessNeoplasmsSurveys and QuestionnairesActivities of Daily Living030212 general & internal medicineLongitudinal StudiesProspective StudiesProspective cohort studyPrimary caregiverAged 80 and overeducation.field_of_studyFamily caregivers[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyillnessAge FactorsMiddle Agedcomprehensive geriatric assessmentolder patientshumanities3. Good healthcomorbidityOncologyCaregivers030220 oncology & carcinogenesisdepressionDisease ProgressionimpactFemalefamily caregiversoncology consultationQuality of lifemedicine.medical_specialtyGeriatric oncology consultationPopulationBurden[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology03 medical and health sciencesmedicineHumanscareeducationbreast-cancerbusiness.industrymedicine.diseaseComorbidityPhysical therapyObservational studyGeriatrics and Gerontologybusiness
researchProduct

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 coun…

2015

Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the eff ectiveness of health systems, and to inform global policy on cancer control. Methods Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15–99 years) and 75 000 children (age 0–14 years) diagnosed with cancer during 1995–2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardise…

Maleeurope 1999-2007PathologyCàncer -- EstadístiquesSurvival[SDV]Life Sciences [q-bio]2700 General MedicineGlobal HealthSettore MED/42 - Igiene Generale E ApplicataNeoplasms80 and overGlobal healthRegistriesStomach cancerChildcancer survivalBreast-cancerComputingMilieux_MISCELLANEOUScancer registry; cancer survival; worldwideCervical cancerAged 80 and overeducation.field_of_studychildhood-cancerMedicine (all)1. No povertyGeneral Medicinecancer survival; population-based registries; surveillanceMiddle Aged3. Good healthovarian-cancerChild Preschoolpopulation-based registriesurveillance/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalenet survivalNeoplasms/mortalityBreast-cancer; childhood-cancer; rectal-cancer; nordic countries; europe 1999-2007; ovarian-cancer; net survival; data quality; care; stageAdultmedicine.medical_specialtyAdolescentPopulationSocio-culturale610 Medicine & healthAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Child; Child Preschool; Female; Global Health; Humans; Infant; Infant Newborn; Male; Middle Aged; Neoplasms; Registries; Sex Distribution; Survival Analysis; Young Adult; Medicine (all)Articlerectal-cancerYoung AdultBreast cancerAge DistributionSDG 3 - Good Health and Well-beingcancer survival; cancer registriesmedicinedata qualityHumanscareSex DistributionPreschooleducationSupervivèncianordic countriesSurvival analysisddc:613AgedCancer -- Statisticsbusiness.industryInfant NewbornCancerInfant10060 Epidemiology Biostatistics and Prevention Institute (EBPI)Newbornmedicine.diseasestageSurvival AnalysisCancer registrycancer registriesbusinessDemography
researchProduct

Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers

2011

[Background]: Germline mutations in the BRCA1 and BRCA2 genes are associated with increased risks of breast and ovarian cancers. Although several common variants have been associated with breast cancer susceptibility in mutation carriers, none have been associated with ovarian cancer susceptibility. A genome-wide association study recently identified an association between the rare allele of the single-nucleotide polymorphism (SNP) rs3814113 (ie, the C allele) at 9p22.2 and decreased risk of ovarian cancer for women in the general population. We evaluated the association of this SNP with ovarian cancer risk among BRCA1 or BRCA2 mutation carriers by use of data from the Consortium of Investi…

OncologyCancer Researchendocrine system diseasesGenes BRCA2Genes BRCA1Genome-wide association studyFAMILIES0302 clinical medicineRisk FactorsRetrospective StudieGenotypeOdds Ratioskin and connective tissue diseasesPOPULATIONGeneticsOvarian NeoplasmsAged 80 and overAllele0303 health scienceseducation.field_of_studyLikelihood FunctionsArticlesGERMLINE MUTATIONSMiddle AgedLikelihood Functionfemale genital diseases and pregnancy complications3. Good healthOncology030220 oncology & carcinogenesisFemaleChromosomes Human Pair 9HumanAdult[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]medicine.medical_specialtyHeterozygoteSUSCEPTIBILITY LOCIGenotypePROTEINSPopulationBiologyPolymorphism Single NucleotideBASONUCLIN-203 medical and health sciencesBreast cancerGermline mutationSDG 3 - Good Health and Well-beingInternal medicinemedicineBREAST-CANCERHumansGENOME-WIDE ASSOCIATIONeducationAllelesGerm-Line Mutation030304 developmental biologyRetrospective StudiesAgedIDENTIFICATIONRisk FactorOvarian NeoplasmEditorialsCancermedicine.diseaseMinor allele frequencyOvarian cancer
researchProduct

Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

2006

Item does not contain fulltext BACKGROUND: Loss of TP53 function through gene mutation is a critical event in the development and progression of many tumour types including colorectal cancer (CRC). In vitro studies have found considerable heterogeneity amongst different TP53 mutants in terms of their transactivating abilities. The aim of this work was to evaluate whether TP53 mutations classified as functionally inactive (< or=20% of wildtype transactivation ability) had different prognostic and predictive values in CRC compared with mutations that retained significant activity. MATERIALS AND METHODS: TP53 mutations within a large, international database of CRC (n = 3583) were classified ac…

Oncologyp53MaleNutrition and Diseasebinding domainsLymphovascular invasionColorectal cancerDNA Mutational AnalysisAetiology screening and detection [ONCOL 5]Gene mutationmedicine.disease_causeTransactivationVoeding en ZiekteAntineoplastic Combined Chemotherapy ProtocolsDeterminants in Health and Disease [EBP 1]transcriptional activityMutationHematologyExonsMiddle AgedSurvival RateOncologyAdenocarcinomaFemaleColorectal Neoplasmsmedicine.medical_specialtyAdenocarcinomachemotherapy colorectal cancer mutation prognosis TP53 transactivational abilityMolecular epidemiology [NCEBP 1]Breast cancerTranslational research [ONCOL 3]Interventional oncology [UMCN 1.5]Internal medicinemedicineHumansNeoplasm InvasivenessSurvival rateneoplasmsbreast-cancerVLAGAgedNeoplasm StagingHereditary cancer and cancer-related syndromes [ONCOL 1]business.industryInternational Agenciesmedicine.diseaseImmunologyMutationTumor Suppressor Protein p53businessFollow-Up Studies
researchProduct